Paper39304574
Chemokine Receptor 4-Targeted PET/CT with [68Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [68Ga]pentixafor PET/CT.
Yang Q and 4 others. Mol Imaging Biol, 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Chemokine Receptor 4-Targeted PET/CT with [68Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [68Ga]pentixafor PET/CT. Papers, record 39304574. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39304574
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Chemokine Receptor 4-Targeted PET/CT with [68Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [68Ga]pentixafor PET/CT.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Positron Emission Tomography Computed Tomography | Major topic |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Aged | |
| Aged, 80 and over | |
| Peptides, Cyclic | |
| Adult | |
| Tumor Burden | |
| Gallium Radioisotopes | |
| Coordination Complexes |
Source PubMed
Grants9
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Grant No. 2022-2-4013 | the Capital Health Development Scientific Research Fund | PubMed | ||
| 2022-PUMCH-B-048 | National High Level Hospital Clinical Research Funding | PubMed | ||
| XH-QN-012K | National High Level Hospital Clinical Research Funding | PubMed | ||
| 2022-PUMCH-D-001 | National High Level Hospital Clinical Research Funding | PubMed | ||
| 2016YFC0901500 | National Key Research and Development Program of China | PubMed | ||
| CIFMS-2021-I2M-1-025 | CAMS innovation fund for medical science | PubMed | ||
| CIFMS-2021-I2M-1-002 | CAMS innovation fund for medical science | PubMed | ||
| CIFMS-2021-I2M-1-003 | CAMS innovation fund for medical science | PubMed | ||
| 82071967 | National Natural Science Foundation of China | PubMed |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28744319 | [177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. | Theranostics | 2017 | https://conductscience.org/library/papers/28744319 | PubMed |
| 2 | 21900099 | Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21900099 | PubMed |
| 3 | 18332230 | Multiple myeloma. | Blood | 2008 | https://conductscience.org/library/papers/18332230 | PubMed |
| 4 | 19443657 | F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. | Blood | 2009 | https://conductscience.org/library/papers/19443657 | PubMed |
| 5 | 34413147 | Biokinetics and Dosimetry of 177Lu-Pentixather. | J Nucl Med | 2022 | https://conductscience.org/library/papers/34413147 | PubMed |
| 6 | 17119115 | Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. | Blood | 2007 | https://conductscience.org/library/papers/17119115 | PubMed |
| 7 | 28042328 | [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values. | Theranostics | 2017 | https://conductscience.org/library/papers/28042328 | PubMed |
| 8 | 31776631 | Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT. | Eur J Nucl Med Mol Imaging | 2020 | https://conductscience.org/library/papers/31776631 | PubMed |
| 9 | 35103762 | Diagnosis and Management of Multiple Myeloma: A Review. | JAMA | 2022 | https://conductscience.org/library/papers/35103762 | PubMed |
| 10 | 15809451 | International staging system for multiple myeloma. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15809451 | PubMed |
| 11 | 34727187 | How I treat high-risk multiple myeloma. | Blood | 2022 | https://conductscience.org/library/papers/34727187 | PubMed |
| 12 | 22045705 | CXCR4-based imaging agents. | J Nucl Med | 2011 | https://conductscience.org/library/papers/22045705 | PubMed |
| 13 | 35674738 | CXCR4-targeted theranostics in oncology. | Eur J Nucl Med Mol Imaging | 2022 | https://conductscience.org/library/papers/35674738 | PubMed |
| 14 | 28432222 | Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. | Blood | 2017 | https://conductscience.org/library/papers/28432222 | PubMed |
| 15 | 25439696 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/25439696 | PubMed |
| 16 | 26564323 | First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. | J Nucl Med | 2016 | https://conductscience.org/library/papers/26564323 | PubMed |
| 17 | 25736399 | In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. | EMBO Mol Med | 2015 | https://conductscience.org/library/papers/25736399 | PubMed |
| 18 | 28529638 | CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. | Theranostics | 2017 | https://conductscience.org/library/papers/28529638 | PubMed |
| 19 | 33918655 | Role and Therapeutic Targeting of SDF-1α/CXCR4 Axis in Multiple Myeloma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33918655 | PubMed |
| 20 | 30850502 | Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation. | J Nucl Med | 2019 | https://conductscience.org/library/papers/30850502 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42244984 | The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015-2025). | Theranostics | 2026 | https://conductscience.org/library/papers/42244984 | PubMed |
| 41760826 | [68Ga]Ga-Pentixafor PET/CT for Durie-Salmon PLUS staging and risk stratification in newly diagnosed multiple myeloma. | Eur J Nucl Med Mol Imaging | 2026 | https://conductscience.org/library/papers/41760826 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39304574
GET https://conductscience.org/api/papers/v1/39304574/references?page=2